UK Study Finds HBIG-Free Prophylaxis Viable After Liver Transplant for Hep B
A 13-year UK analysis of 273 liver transplant patients finds HBIG maintenance may be unnecessary, with NA-only prophylaxis offering a cost-effective alternative.
Summary
A major UK retrospective study spanning 2010–2023 examined how hepatitis B immunoglobulin (HBIG) is used after liver transplantation across seven transplant centers. Despite wide variation in protocols, outcomes were similar regardless of HBIG dose or duration. Only 5.1% of patients experienced HBV recurrence within 12 months, and the main risk factor was triple immunosuppression — not HBIG regimen. Survival rates were strong at 98.2% at one year and 80.6% at seven years. The findings suggest that indefinite HBIG maintenance — an expensive standard practice — may be unnecessary for most patients, and that nucleoside analogue-only prophylaxis could be a safe, cost-effective alternative. Prospective trials are needed to confirm this shift in practice.
Detailed Summary
Hepatitis B virus (HBV) recurrence after liver transplantation has historically been prevented using a combination of hepatitis B immunoglobulin (HBIG) and nucleos(t)ide analogues (NAs). HBIG is expensive, requires ongoing administration, and protocols vary widely between centers — raising questions about whether indefinite use is truly necessary.
This retrospective UK study analyzed all HBV-related liver transplants performed between 2010 and 2023 across seven major transplant centers, covering 273 patients. Researchers assessed post-transplant HBV prophylaxis protocols, recurrence rates, survival outcomes, and the cost implications of different HBIG strategies.
Despite 81.7% of patients being classified as high risk for HBV recurrence, outcomes did not differ meaningfully based on HBIG dose or duration. HBV recurrence occurred in just 5.1% of patients within 12 months. Multivariate analysis identified triple immunosuppression as the only significant independent predictor of recurrence. Survival at one, five, and seven years was 98.2%, 88.3%, and 80.6%, respectively. Notably, only lower IV HBIG doses in the first week post-transplant were associated with increased seven-year mortality — suggesting early dosing may matter more than long-term maintenance.
The study found enormous variation in HBIG protocols across UK centers, with 54.6% of patients continuing HBIG for a median of 119 days. This inconsistency, combined with the lack of outcome differences, supports a move toward HBIG-free maintenance strategies using NAs alone for most patients.
Caveats include the retrospective design, potential selection bias across centers, and the fact that this summary is based on the abstract only. Prospective randomized studies are needed to validate HBIG-free protocols and guide standardized national guidelines.
Key Findings
- HBV recurrence occurred in only 5.1% of patients within 12 months post-liver transplant.
- Triple immunosuppression — not HBIG dose or duration — was the key independent predictor of HBV recurrence.
- Survival rates were strong: 98.2% at 1 year, 88.3% at 5 years, and 80.6% at 7 years.
- Wide variation in HBIG protocols across UK centers produced no meaningful difference in outcomes.
- HBIG-free maintenance prophylaxis using nucleoside analogues alone appears feasible and cost-effective for most patients.
Methodology
Retrospective cohort study of 273 HBV-related liver transplants across seven UK centers from 2010 to 2023. Outcomes assessed included HBV recurrence, overall survival, and HBIG cost comparisons across protocols. Multivariate and Cox regression analyses were used to identify predictors of recurrence and mortality.
Study Limitations
The retrospective design introduces potential selection bias and confounding across heterogeneous center protocols. Summary is based on the abstract only, so full methodology, patient subgroup analyses, and cost data cannot be fully evaluated. Prospective randomized trials are required before HBIG-free strategies can be broadly adopted as standard of care.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.